Dynavax Technologies Corporation has reported its financial results for the first quarter of 2025, highlighting a significant increase in revenue and market share. Total revenue reached $68.2 million, marking a 34% rise compared to $50.8 million in the same quarter of 2024. The net product revenue for HEPLISAV-B® was $65 million, representing a 36% increase from $47.8 million in the previous year's first quarter. The company's HEPLISAV-B® total estimated U.S. market share also grew to approximately 43%, up from about 41% in Q1 2024. Adjusted EBITDA improved to negative $4 million, compared to negative $7 million in Q1 2024, with expectations for Adjusted EBITDA to reach at least $75 million by the end of 2025. Dynavax has executed over 85% of its $200 million share repurchase program, with $172 million completed as of May 5, 2025. The company continues to advance its vaccine pipeline, leveraging its proprietary CpG 1018 adjuvant, and has announced new pipeline programs alongside their ongoing shingles and plague vaccine initiatives.